Liquid Biopsy 2019

DESCRIPTION

On 26 & 27 September 2019, Milan (Italy) will host the BioTech Pharma Summit: Liquid Biopsy 2019 conference. This year’s event will bring together the leaders in the field from pharma, biotech, Dx companies and healthcare and be the home of multi-stakeholder and pan-industry collaboration for liquid biopsy, molecular pathology and precision medicine experts to explore the expanding and evolving field whereby Circulating Biomarkers of various classes are being evaluated for their potential to be developed into diagnostics for cancer as well as application of liquid biopsy testing, across biofluids, biomarkers and disease indications, as the needle shifts on the gold standard of personalized healthcare testing.

Latest findings on the clinical applications of CTCs, ctDNA, miRNAs and exosomes in real time monitoring of systemic anticancer therapies will be discussed only at the Liquid Biopsy 2019

The field of liquid biopsy is moving beyond isolation and characterization of CTCs and ctDNA to surveillance, early detection of relapse and minimal residual disease, and interventional studies in clinical applications. The scope of the conference encompasses circulating tumor cells, cell-free circulating DNA, exosomes and extracellular vesicles. This meeting has become an important annual event for leaders in the community to discuss the tools, validation and implementation of circulating biomarkers, which are transforming our understanding and management of disease.

At the Liquid Biopsy 2019, experts present and consider process and technology refinements that can enable molecular liquid biopsies to become a fulcrum in the future of precision medicine.

The BioTech Pharma Summit: Liquid Biopsy 2019 focuses primarily on biofluid-based molecular biomarkers, such as circulating tumor DNA (ctDNA) as well as circulating tumor cells (CTCs), and protein-based circulating biomarkers. There is much interest in the potential of ctDNA for developing biological fluid-based biopsies (such as using plasma, urine, or other biofluids) and the presenters in this track bring together the most up-to-date information and current state-of-the-field.

 

KEY PRACTICAL LEARNING POINTS

  • Liquid Biopsy: New Opportunities and Challenges in the Field
  • Clinical integration of liquid biopsy
  • Pre-Analytical Variables in Blood Collection Impact on Precision Medicine
  • Liquid Biopsy for Brain Tumors
  • Circulating Tumor Cells: History and Future Perspectives
  • Improving the Quality of Circulating Tumor DNA Measurements
  • Circulating Tumor Cells in Monitoring Cancer
  • Phenogenomic Subtyping of CTCs
  • Retrospective Analysis of CellSearch CTC Enumeration Data across Clinical Trials
  • CTC Isolation Platforms and Using CTCs for Monitoring Therapy Responses
  • Using Microscale Devices to Characterize the Role of Extracellular Shed Vesicles in Drug Resistance in Cancer
  • Liquid Biopsy: Immune Interactions
  • Dissecting Mechanisms of Breast Cancer Metastasis Using Patient-Derived Circulating Tumor Cells
  • Multi-Component Liquid Biopsy Enabled by High-Throughput Optical Scanning Technologies
  • Liquid Biopsy in Neurovascular Inflammation
  • Detection of Human Cardiomyocyte Death Using Cell-Free DNA
  • Liquid Biopsies in Cancer Immunotherapy Clinical Drug Development
  • Microfluidic Cell Tethering to Rapidly Measure Drug Responses in Patient Tumor Cells
  • Epigenetic and Genetic Analysis of Circulating Biomarkers for Prostate Cancer Prognosis
  • Heterogeneity of Cancer-Derived Extracellular Vesicles
  • Clinical Utility Needs of ctDNA Assays versus Research Utility
  • Liquid Biopsies in Oncology and the Current Regulatory Landscape
  • Validating Liquid Biopsies in Cancer: How Sensitive Is Clinically Meaningful?
  • ctDNA Liquid Biopsy Assay for Colorectal Cancer
  • Development and Validation of a Pan-Cancer Liquid Biopsy Test
  • Analyzing Other Liquid Fractions in the Body
  • Optofluidic Systems for On-Chip Detection of Cancer and Infectious Disease Biomarkers
  • New Tools for Liquid Biopsies: Microfluidic Platforms for the Isolation of CTCs, cfDNA and Exosomes
  • Commercializing isolation of CTCs: Price point/low cost, Manufacturability, Market outlook, Supply chain management

WHO SHOULD ATTEND?

The BioTech Pharma Summit (EPM Group) are exclusive events consisting of world-class keynote addresses and presentations designed specifically for senior level attendees from research & academic institutions, clinical research institutions and hospital laboratories as well as major pharmaceutical and biotech companies based Worldwide. Delegates typically include CEOs, VPs, Drug developers, Academics and Researchers, CROs, Scientists and Medical Doctors of:

  • Liquid biopsy
  • Clinical Pathology
  • Molecular Assay Development
  • Medical Laboratory
  • Scientific Affairs
  • Sales and Marketing
  • Quality Management
  • Process Development
  • Commercial & Outreach, Oncology
  • Molecular pathology
  • Research Scientist
  • Molecular Biology
  • Sales & Business Development
  • Clinical and Translational Affairs
  • Clinical Research
  • Companion Diagnostics
  • Biomarkers
  • Manufacturing
  • Scientific Affairs
  • Clinical Trial
  • Oncology Business Development
  • Precision medicine
  • Clinical Laboratory
  • Immunochemistry
  • Cell Culture
  • Clinical Genomics